摘要
免疫调节药物雷那度胺是沙利度胺的4-氨基-谷氨酰基衍生物,较沙利度胺更为安全、有效,对多种造血肿瘤和实体瘤有效,美国FDA将其批准用于治疗5q-骨髓增生异常综合征、多发性骨髓瘤。雷那度胺通过调节免疫、抗血管生成、影响信号传导等多种机制在造血肿瘤中发挥抗肿瘤活性。本文就这些问题的研究进展作一综述。
Immunomodulatory drug lenalidomide is a synthetic compound derived by modifying the chemical struc- ture of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that has emerged as a drug with activity against various hematological and solid malignancies. It is approved by FDA in USA for clinical use in myelodysplastic syndromes with deletion of chromosome 5q and multiple myeloma. Studies have shown that lenalidomide exert anti-tumor activity probably by various mechanisms in hematologic malignan- cies, such as immunomodulation, anti-angiogenesis and effects on signal transduction. In this article, the progresses of study on these problems are reviewed.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2012年第4期1039-1041,共3页
Journal of Experimental Hematology
关键词
免疫调节药物
雷那度胺
血液肿瘤
immunomodulatory drug
lenalidomide
hematological malignancy
